Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583830 · ClinicalTrials.gov registry record · Phase 2
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00583830 is a Phase 2 study that has completed, run by Human Genome Sciences. The registered enrollment target is 111 participants.
The verdict
NCT00583830, a Phase 2 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Mapatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583830
The ClinicalTrials.gov registry entry for NCT00583830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00583830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583830 about?
NCT00583830 is a clinical study titled "A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer". The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00583830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2007-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00583830?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Mapatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00583830?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.